We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-15.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$307M
AUM Growth
-$111M
Cap. Flow
-$25.2M
Cap. Flow %
-8.21%
Top 10 Hldgs %
66.99%
Holding
55
New
8
Increased
13
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26.3M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$16.1M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.82M
4
IGMS
IGM Biosciences
IGMS
+$1.68M
5
GOSS icon
Gossamer Bio
GOSS
+$1.6M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.79M
2
TELA icon
TELA Bio
TELA
+$7.71M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.21M
4
TBPH icon
Theravance Biopharma
TBPH
+$5.63M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$5.57M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$54.5M 17.74%
3,795,000
+20,000
+0.5% +$350K
SLRN
2
DELISTED
ACELYRIN
SLRN
$42.2M 13.72%
4,146,138
-12,500
-0.3% -$265K
OCUL icon
3
Ocular Therapeutix
OCUL
$2.38B
$20.3M 6.61%
6,468,000
+688,000
+12% +$2.82M
TGTX icon
4
TG Therapeutics
TGTX
$8.53B
$15.8M 5.14%
+1,890,000
New +$26.3M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.75B
$15M 4.87%
653,000
-82,000
-11% -$1.84M
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$14.1M 4.58%
+1,205,000
New +$16.1M
KROS icon
7
Keros Therapeutics
KROS
$223M
$11.5M 3.74%
360,400
+7,750
+2% +$289K
BHVN icon
8
Biohaven
BHVN
$2.43B
$11.4M 3.71%
439,000
-101,000
-19% -$2.1M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$9B
$11M 3.58%
370,000
-475,000
-56% -$9.79M
ETON icon
10
Eton Pharmaceutcials
ETON
$1.79B
$10.1M 3.3%
2,430,270
+145,270
+6% +$561K
IDYA icon
11
IDEAYA Biosciences
IDYA
$4.03B
$8.4M 2.73%
311,500
-103,500
-25% -$2.62M
MOR
12
DELISTED
MorphoSys AG American Depositary Shares
MOR
$8.13M 2.64%
1,209,380
– –
TELA icon
13
TELA Bio
TELA
$29.2M
$6M 1.95%
750,000
-830,000
-53% -$7.71M
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.8B
$5.02M 1.63%
875,405
+60,405
+7% +$411K
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$4.82M 1.57%
500,000
-220,000
-31% -$2.25M
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.7M 1.53%
584,000
-41,000
-7% -$341K
PCVX icon
17
Vaxcyte
PCVX
$9.1B
$4.59M 1.49%
90,000
-87,000
-49% -$4.29M
TARA icon
18
Protara Therapeutics
TARA
$236M
$4.5M 1.46%
2,692,594
– –
URGN icon
19
UroGen Pharma
URGN
$2.22B
$4.48M 1.46%
320,000
-250,000
-44% -$4.01M
GERN icon
20
Geron
GERN
$983M
$4.06M 1.32%
1,915,000
-435,000
-19% -$1.18M
GOSS icon
21
Gossamer Bio
GOSS
$83.2M
$3.96M 1.29%
4,754,200
+1,384,200
+41% +$1.6M
FDMT icon
22
4D Molecular Therapeutics
FDMT
$824M
$3.93M 1.28%
308,500
+86,800
+39% +$1.45M
XOMA
23
DELISTED
Xoma
XOMA
$3.87M 1.26%
274,500
-500
-0.2% -$7.84K
TRVI icon
24
Trevi Therapeutics
TRVI
$2.56B
$3.72M 1.21%
1,705,900
+4,400
+0.3% +$9.94K
LQDA icon
25
Liquidia Corp
LQDA
$6.26B
$3.62M 1.18%
570,700
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2023 Portfolio in Review

As of Q3 2023, Opaleye Management held 55 positions worth $307M, down 26% from $418M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Opaleye Management withdrew a net $25.2M in Q3 2023, closing 15 positions and reducing 15 holdings. Its most notable exit was Cymabay Therapeutics, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in TG Therapeutics worth $15.8M.

  • Opaleye Management's largest Q3 2023 buy was TG Therapeutics: 1,890,000 shares worth $15.8M.
  • Opaleye Management added most to Ocular Therapeutix in Q3 2023, an estimated $2.82M increase.
  • Opaleye Management's biggest Q3 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $9.79M.
  • Opaleye Management fully exited Cymabay Therapeutics in Q3 2023, selling an estimated $6.21M.
  • Opaleye Management's ten largest holdings make up 67% of its $307M portfolio in Q3 2023.
  • Opaleye Management opened 8 new positions and closed 15 in Q3 2023.
  • Opaleye Management's portfolio value fell 26% quarter-over-quarter to $307M.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.